| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccines, DNA | 42 | 2024 | 98 | 9.900 |
Why?
|
| AIDS Vaccines | 25 | 2024 | 72 | 6.310 |
Why?
|
| HIV Envelope Protein gp120 | 21 | 2024 | 134 | 4.870 |
Why?
|
| HIV Antibodies | 23 | 2024 | 148 | 4.790 |
Why?
|
| HIV-1 | 21 | 2024 | 723 | 2.820 |
Why?
|
| Antibodies, Neutralizing | 15 | 2024 | 214 | 2.450 |
Why?
|
| Antibodies, Viral | 11 | 2014 | 329 | 2.180 |
Why?
|
| HIV Infections | 14 | 2024 | 976 | 1.820 |
Why?
|
| Viral Vaccines | 6 | 2020 | 54 | 1.810 |
Why?
|
| Immunization, Secondary | 12 | 2024 | 50 | 1.760 |
Why?
|
| Adjuvants, Immunologic | 6 | 2014 | 230 | 1.330 |
Why?
|
| Plague | 5 | 2011 | 23 | 1.210 |
Why?
|
| Neutralization Tests | 19 | 2018 | 127 | 1.200 |
Why?
|
| Immunization | 9 | 2014 | 135 | 1.190 |
Why?
|
| Influenza Vaccines | 4 | 2013 | 101 | 1.180 |
Why?
|
| Vaccination | 7 | 2018 | 371 | 1.120 |
Why?
|
| Rabbits | 15 | 2017 | 333 | 1.100 |
Why?
|
| Influenza, Human | 4 | 2014 | 212 | 1.050 |
Why?
|
| CD4 Antigens | 3 | 2024 | 151 | 1.030 |
Why?
|
| Virus Diseases | 3 | 2014 | 123 | 1.000 |
Why?
|
| Animals | 47 | 2021 | 20962 | 1.000 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 4 | 2018 | 60 | 0.940 |
Why?
|
| Vaccines, Subunit | 9 | 2017 | 40 | 0.930 |
Why?
|
| T-Lymphocytes | 8 | 2015 | 1019 | 0.920 |
Why?
|
| Mice, Inbred BALB C | 15 | 2014 | 891 | 0.910 |
Why?
|
| Antigens, Bacterial | 5 | 2016 | 200 | 0.900 |
Why?
|
| Epitopes | 5 | 2020 | 292 | 0.860 |
Why?
|
| Yersinia pestis | 6 | 2014 | 33 | 0.820 |
Why?
|
| Plague Vaccine | 3 | 2010 | 5 | 0.820 |
Why?
|
| Vaccines | 2 | 2017 | 98 | 0.760 |
Why?
|
| Antibody-Producing Cells | 1 | 2021 | 12 | 0.730 |
Why?
|
| Antibody Formation | 4 | 2017 | 114 | 0.720 |
Why?
|
| Technology, Pharmaceutical | 2 | 2014 | 20 | 0.720 |
Why?
|
| Antibodies, Monoclonal | 6 | 2024 | 870 | 0.720 |
Why?
|
| Hemagglutinins, Viral | 2 | 2014 | 12 | 0.720 |
Why?
|
| Immunoglobulin G | 13 | 2020 | 463 | 0.710 |
Why?
|
| Cytokines | 4 | 2014 | 944 | 0.700 |
Why?
|
| Immunity, Cellular | 5 | 2011 | 178 | 0.680 |
Why?
|
| Codon | 3 | 2006 | 57 | 0.680 |
Why?
|
| Cytomegalovirus Vaccines | 2 | 2013 | 5 | 0.670 |
Why?
|
| DNA | 3 | 2018 | 844 | 0.650 |
Why?
|
| Cytomegalovirus | 4 | 2013 | 94 | 0.650 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2013 | 42 | 0.640 |
Why?
|
| Mice | 25 | 2021 | 11003 | 0.640 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 4 | 2014 | 91 | 0.640 |
Why?
|
| Polysaccharides | 2 | 2020 | 151 | 0.620 |
Why?
|
| Immunity, Innate | 2 | 2015 | 803 | 0.600 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 9 | 2013 | 458 | 0.580 |
Why?
|
| Science | 1 | 2019 | 34 | 0.570 |
Why?
|
| B-Lymphocytes | 3 | 2018 | 572 | 0.560 |
Why?
|
| Betacoronavirus | 1 | 2020 | 183 | 0.550 |
Why?
|
| Humans | 49 | 2024 | 64279 | 0.550 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2017 | 34 | 0.540 |
Why?
|
| Racism | 1 | 2019 | 88 | 0.530 |
Why?
|
| Viral Envelope Proteins | 3 | 2007 | 102 | 0.510 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 210 | 0.510 |
Why?
|
| Vaccinia virus | 2 | 2007 | 73 | 0.510 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.500 |
Why?
|
| Immunologic Factors | 1 | 2017 | 109 | 0.500 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2014 | 204 | 0.500 |
Why?
|
| Biotechnology | 2 | 2014 | 45 | 0.480 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2015 | 33 | 0.480 |
Why?
|
| HIV Antigens | 5 | 2010 | 18 | 0.470 |
Why?
|
| Saponins | 3 | 2014 | 29 | 0.460 |
Why?
|
| Pore Forming Cytotoxic Proteins | 3 | 2011 | 38 | 0.460 |
Why?
|
| Nucleotidyltransferases | 1 | 2015 | 63 | 0.450 |
Why?
|
| Phospholipids | 1 | 2014 | 82 | 0.410 |
Why?
|
| DNA-Binding Proteins | 3 | 2014 | 1196 | 0.400 |
Why?
|
| Respiratory Tract Infections | 1 | 2014 | 90 | 0.400 |
Why?
|
| Viruses | 1 | 2014 | 81 | 0.400 |
Why?
|
| Female | 27 | 2024 | 33382 | 0.390 |
Why?
|
| Protein Engineering | 3 | 2010 | 85 | 0.390 |
Why?
|
| Antigens, Viral | 3 | 2008 | 137 | 0.380 |
Why?
|
| Cholesterol | 1 | 2014 | 260 | 0.380 |
Why?
|
| Vaccines, Attenuated | 2 | 2013 | 36 | 0.370 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 89 | 0.370 |
Why?
|
| Interferon-gamma | 7 | 2013 | 576 | 0.360 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2011 | 12 | 0.360 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 166 | 0.350 |
Why?
|
| Gene Transfer Techniques | 2 | 2004 | 324 | 0.350 |
Why?
|
| HIV | 1 | 2011 | 70 | 0.350 |
Why?
|
| Cancer Vaccines | 2 | 2009 | 52 | 0.340 |
Why?
|
| Bacterial Infections | 1 | 2012 | 153 | 0.340 |
Why?
|
| Inflammasomes | 1 | 2014 | 342 | 0.340 |
Why?
|
| Bacterial Vaccines | 1 | 2011 | 81 | 0.320 |
Why?
|
| Antibody Affinity | 1 | 2010 | 19 | 0.320 |
Why?
|
| Biological Warfare | 1 | 2009 | 4 | 0.320 |
Why?
|
| Membrane Proteins | 1 | 2015 | 909 | 0.310 |
Why?
|
| Electroporation | 2 | 2013 | 35 | 0.310 |
Why?
|
| Viral Tropism | 3 | 2018 | 53 | 0.310 |
Why?
|
| Cross Reactions | 4 | 2016 | 134 | 0.300 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2011 | 679 | 0.290 |
Why?
|
| HEK293 Cells | 2 | 2021 | 627 | 0.290 |
Why?
|
| Severe Acute Respiratory Syndrome | 2 | 2005 | 23 | 0.280 |
Why?
|
| Mice, Inbred C57BL | 5 | 2017 | 3450 | 0.280 |
Why?
|
| Plasmids | 5 | 2008 | 293 | 0.280 |
Why?
|
| Smallpox | 1 | 2007 | 10 | 0.270 |
Why?
|
| Immunity, Mucosal | 1 | 2008 | 52 | 0.270 |
Why?
|
| Smallpox Vaccine | 1 | 2007 | 16 | 0.270 |
Why?
|
| Enzyme-Linked Immunospot Assay | 3 | 2018 | 12 | 0.250 |
Why?
|
| Prions | 1 | 2006 | 24 | 0.250 |
Why?
|
| Virus Replication | 3 | 2013 | 323 | 0.250 |
Why?
|
| Transfection | 3 | 2013 | 695 | 0.250 |
Why?
|
| Vaccinia | 1 | 2006 | 32 | 0.250 |
Why?
|
| DNA, Viral | 2 | 2011 | 234 | 0.250 |
Why?
|
| Glycosylation | 3 | 2020 | 138 | 0.240 |
Why?
|
| Gene Products, env | 1 | 2005 | 18 | 0.230 |
Why?
|
| DNA, Recombinant | 1 | 2005 | 47 | 0.230 |
Why?
|
| Influenza A virus | 1 | 2006 | 124 | 0.230 |
Why?
|
| Membrane Glycoproteins | 2 | 2005 | 671 | 0.220 |
Why?
|
| Cell Line | 7 | 2018 | 2055 | 0.220 |
Why?
|
| Receptors, Complement 3d | 1 | 2004 | 16 | 0.210 |
Why?
|
| Injections, Jet | 1 | 2004 | 1 | 0.210 |
Why?
|
| Complementarity Determining Regions | 1 | 2024 | 38 | 0.210 |
Why?
|
| Microinjections | 1 | 2004 | 69 | 0.210 |
Why?
|
| Microspheres | 1 | 2004 | 57 | 0.210 |
Why?
|
| Immunization Schedule | 2 | 2017 | 18 | 0.200 |
Why?
|
| Vaccines, Synthetic | 3 | 2008 | 78 | 0.200 |
Why?
|
| China | 2 | 2019 | 170 | 0.200 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 685 | 0.190 |
Why?
|
| Cryoelectron Microscopy | 1 | 2024 | 207 | 0.190 |
Why?
|
| Mice, Knockout | 4 | 2015 | 2140 | 0.180 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2020 | 645 | 0.180 |
Why?
|
| ROC Curve | 2 | 2013 | 288 | 0.180 |
Why?
|
| Skin | 2 | 2008 | 386 | 0.180 |
Why?
|
| Hemagglutination Inhibition Tests | 2 | 2014 | 9 | 0.180 |
Why?
|
| Adolescent | 5 | 2024 | 6305 | 0.180 |
Why?
|
| Binding Sites | 1 | 2024 | 914 | 0.180 |
Why?
|
| Gold | 1 | 2004 | 233 | 0.180 |
Why?
|
| Sumoylation | 1 | 2021 | 17 | 0.170 |
Why?
|
| Cricetulus | 2 | 2020 | 100 | 0.170 |
Why?
|
| Adult | 9 | 2024 | 17133 | 0.170 |
Why?
|
| Cytomegalovirus Infections | 2 | 2012 | 68 | 0.170 |
Why?
|
| Recombinant Proteins | 3 | 2020 | 704 | 0.170 |
Why?
|
| CHO Cells | 2 | 2020 | 189 | 0.170 |
Why?
|
| Male | 11 | 2024 | 30323 | 0.170 |
Why?
|
| Vero Cells | 3 | 2005 | 81 | 0.170 |
Why?
|
| Neoplasms | 2 | 2009 | 1392 | 0.170 |
Why?
|
| Human Experimentation | 3 | 2008 | 32 | 0.160 |
Why?
|
| RNA, Small Interfering | 4 | 2021 | 927 | 0.160 |
Why?
|
| Macrophages | 2 | 2018 | 1053 | 0.150 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 116 | 0.150 |
Why?
|
| Protein Domains | 1 | 2020 | 154 | 0.150 |
Why?
|
| Drug Design | 1 | 2020 | 138 | 0.150 |
Why?
|
| Antibody Specificity | 2 | 2010 | 102 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2017 | 313 | 0.140 |
Why?
|
| Nuclear Proteins | 2 | 2021 | 785 | 0.140 |
Why?
|
| Hepatitis B Antibodies | 1 | 2018 | 9 | 0.140 |
Why?
|
| Hepatitis B Vaccines | 1 | 2018 | 15 | 0.140 |
Why?
|
| Hepatitis B virus | 1 | 2018 | 15 | 0.140 |
Why?
|
| Antibodies, Bacterial | 2 | 2010 | 182 | 0.140 |
Why?
|
| Hepatitis B | 1 | 2018 | 33 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2010 | 495 | 0.130 |
Why?
|
| Receptors, CCR5 | 1 | 2018 | 59 | 0.130 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 2 | 2008 | 28 | 0.130 |
Why?
|
| Cells, Cultured | 2 | 2015 | 2177 | 0.130 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 99 | 0.130 |
Why?
|
| Prospective Studies | 3 | 2014 | 3318 | 0.130 |
Why?
|
| Biomarkers | 2 | 2013 | 1431 | 0.130 |
Why?
|
| Vaccines, Inactivated | 2 | 2008 | 14 | 0.130 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2013 | 48 | 0.130 |
Why?
|
| Receptors, Fc | 1 | 2016 | 24 | 0.130 |
Why?
|
| Middle Aged | 6 | 2024 | 17923 | 0.120 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2021 | 430 | 0.120 |
Why?
|
| Body Weight | 2 | 2007 | 379 | 0.120 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2015 | 97 | 0.120 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 2016 | 29 | 0.110 |
Why?
|
| Blotting, Western | 2 | 2008 | 614 | 0.110 |
Why?
|
| Immediate-Early Proteins | 2 | 2012 | 45 | 0.110 |
Why?
|
| Interleukin-18 | 1 | 2014 | 75 | 0.110 |
Why?
|
| Interferon-beta | 1 | 2014 | 80 | 0.110 |
Why?
|
| Interferon-alpha | 1 | 2014 | 103 | 0.110 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 65 | 0.110 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2014 | 34 | 0.110 |
Why?
|
| Lipid A | 1 | 2014 | 66 | 0.110 |
Why?
|
| Caenorhabditis elegans | 1 | 2021 | 685 | 0.110 |
Why?
|
| Genetic Fitness | 1 | 2014 | 36 | 0.110 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2014 | 15 | 0.110 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2005 | 116 | 0.100 |
Why?
|
| Gene Expression | 3 | 2018 | 851 | 0.100 |
Why?
|
| Biolistics | 1 | 2013 | 3 | 0.100 |
Why?
|
| Diarrhea | 1 | 2014 | 76 | 0.100 |
Why?
|
| Feedback, Physiological | 1 | 2013 | 59 | 0.100 |
Why?
|
| Drug Combinations | 1 | 2014 | 168 | 0.100 |
Why?
|
| Injections | 1 | 2013 | 82 | 0.100 |
Why?
|
| Signal Transduction | 3 | 2015 | 3070 | 0.100 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2013 | 38 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2012 | 204 | 0.100 |
Why?
|
| Trans-Activators | 2 | 2012 | 312 | 0.100 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 271 | 0.100 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2014 | 166 | 0.100 |
Why?
|
| Communicable Diseases | 1 | 2014 | 91 | 0.100 |
Why?
|
| Receptors, HIV | 1 | 2012 | 16 | 0.100 |
Why?
|
| Virus Attachment | 1 | 2012 | 18 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 215 | 0.100 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2014 | 351 | 0.100 |
Why?
|
| DNA Damage | 2 | 2012 | 289 | 0.090 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2012 | 76 | 0.090 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2012 | 16 | 0.090 |
Why?
|
| RNA Interference | 2 | 2013 | 618 | 0.090 |
Why?
|
| Host-Pathogen Interactions | 1 | 2014 | 266 | 0.090 |
Why?
|
| Trauma Centers | 1 | 2012 | 127 | 0.090 |
Why?
|
| Genetic Vectors | 2 | 2010 | 889 | 0.090 |
Why?
|
| E2F1 Transcription Factor | 1 | 2011 | 16 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2012 | 608 | 0.090 |
Why?
|
| Lethal Dose 50 | 1 | 2011 | 16 | 0.090 |
Why?
|
| Virology | 1 | 2010 | 15 | 0.080 |
Why?
|
| Genetics, Microbial | 1 | 2010 | 11 | 0.080 |
Why?
|
| Brain | 2 | 2011 | 1581 | 0.080 |
Why?
|
| United States | 2 | 2024 | 7923 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 984 | 0.080 |
Why?
|
| HIV Core Protein p24 | 1 | 2009 | 17 | 0.080 |
Why?
|
| Trisaccharides | 1 | 2009 | 9 | 0.080 |
Why?
|
| Viral Proteins | 1 | 2012 | 266 | 0.080 |
Why?
|
| Lymph Nodes | 1 | 2011 | 229 | 0.080 |
Why?
|
| Interleukin-5 | 1 | 2009 | 39 | 0.080 |
Why?
|
| Disease Progression | 1 | 2014 | 1176 | 0.080 |
Why?
|
| Dimerization | 2 | 2007 | 146 | 0.080 |
Why?
|
| Virulence Factors | 1 | 2010 | 85 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1164 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 1105 | 0.080 |
Why?
|
| Mutation | 2 | 2014 | 2629 | 0.070 |
Why?
|
| Young Adult | 2 | 2024 | 4781 | 0.070 |
Why?
|
| Immunity | 1 | 2009 | 107 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 396 | 0.070 |
Why?
|
| Iridovirus | 1 | 2008 | 4 | 0.070 |
Why?
|
| Orthomyxoviridae | 1 | 2008 | 26 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 800 | 0.070 |
Why?
|
| Plasminogen Activators | 1 | 2008 | 10 | 0.070 |
Why?
|
| Variola virus | 1 | 2007 | 1 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1561 | 0.070 |
Why?
|
| Research | 1 | 2009 | 196 | 0.070 |
Why?
|
| Chemoprevention | 1 | 2007 | 41 | 0.070 |
Why?
|
| Antigens | 1 | 2008 | 149 | 0.070 |
Why?
|
| Antibodies | 1 | 2008 | 186 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2007 | 365 | 0.060 |
Why?
|
| Vaccines, Combined | 1 | 2006 | 9 | 0.060 |
Why?
|
| Models, Animal | 1 | 2007 | 240 | 0.060 |
Why?
|
| Prion Diseases | 1 | 2006 | 10 | 0.060 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2007 | 223 | 0.060 |
Why?
|
| Aged | 2 | 2013 | 14664 | 0.060 |
Why?
|
| Golgi Apparatus | 1 | 2006 | 64 | 0.060 |
Why?
|
| Complement System Proteins | 1 | 2007 | 105 | 0.060 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 1118 | 0.060 |
Why?
|
| Research Design | 1 | 2009 | 583 | 0.060 |
Why?
|
| Escherichia coli | 2 | 2007 | 718 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 1 | 2006 | 178 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2007 | 577 | 0.060 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2005 | 11 | 0.060 |
Why?
|
| Epitope Mapping | 1 | 2005 | 52 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2006 | 279 | 0.060 |
Why?
|
| Kidney | 1 | 2007 | 455 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2006 | 587 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 460 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 674 | 0.060 |
Why?
|
| Colony Count, Microbial | 1 | 2004 | 59 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 329 | 0.050 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2004 | 35 | 0.050 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2024 | 17 | 0.050 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 1597 | 0.050 |
Why?
|
| Models, Molecular | 1 | 2008 | 1159 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 1997 | 0.050 |
Why?
|
| DNA Primers | 1 | 2004 | 295 | 0.050 |
Why?
|
| Administration, Cutaneous | 1 | 2004 | 32 | 0.050 |
Why?
|
| Guinea Pigs | 1 | 2004 | 84 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2004 | 127 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 544 | 0.050 |
Why?
|
| Species Specificity | 1 | 2004 | 334 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 5528 | 0.050 |
Why?
|
| Macaca mulatta | 1 | 2004 | 256 | 0.050 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2013 | 42 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 727 | 0.050 |
Why?
|
| Immunoblotting | 2 | 2013 | 206 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2024 | 744 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2013 | 234 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2008 | 775 | 0.050 |
Why?
|
| Meiosis | 1 | 2021 | 67 | 0.040 |
Why?
|
| Ovum | 1 | 2021 | 63 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 1683 | 0.040 |
Why?
|
| Rats | 1 | 2004 | 2005 | 0.040 |
Why?
|
| Argonaute Proteins | 1 | 2021 | 145 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1551 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 2238 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2018 | 182 | 0.030 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2018 | 184 | 0.030 |
Why?
|
| Volunteers | 1 | 2016 | 17 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2018 | 668 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2018 | 417 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1365 | 0.030 |
Why?
|
| Phosphoenolpyruvate Sugar Phosphotransferase System | 1 | 2014 | 2 | 0.030 |
Why?
|
| Aluminum Hydroxide | 1 | 2014 | 3 | 0.030 |
Why?
|
| Thiazoles | 1 | 2014 | 47 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 1020 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2014 | 89 | 0.030 |
Why?
|
| Gene Library | 1 | 2014 | 102 | 0.030 |
Why?
|
| Genes, Immediate-Early | 1 | 2013 | 9 | 0.030 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2013 | 30 | 0.030 |
Why?
|
| Phenols | 1 | 2014 | 82 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1618 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2014 | 374 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 209 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 668 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 759 | 0.020 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2012 | 15 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2014 | 290 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 930 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2013 | 239 | 0.020 |
Why?
|
| Protein Transport | 1 | 2013 | 405 | 0.020 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2011 | 27 | 0.020 |
Why?
|
| Caffeine | 1 | 2011 | 46 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 319 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1270 | 0.020 |
Why?
|
| Galactosyltransferases | 1 | 2009 | 16 | 0.020 |
Why?
|
| Molecular Biology | 1 | 2010 | 67 | 0.020 |
Why?
|
| Immunity, Humoral | 1 | 2009 | 39 | 0.020 |
Why?
|
| DNA Repair | 1 | 2011 | 250 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2011 | 404 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2009 | 34 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2008 | 19 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2009 | 137 | 0.020 |
Why?
|
| Vasculitis | 1 | 2008 | 50 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 2605 | 0.020 |
Why?
|
| Histones | 1 | 2011 | 486 | 0.020 |
Why?
|
| Models, Biological | 1 | 2012 | 1187 | 0.020 |
Why?
|
| Virulence | 1 | 2007 | 195 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 2006 | 52 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2006 | 41 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2007 | 161 | 0.020 |
Why?
|
| Cricetinae | 1 | 2006 | 368 | 0.010 |
Why?
|
| Risk Factors | 1 | 2014 | 5342 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2012 | 1540 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 1621 | 0.010 |
Why?
|